Akero Therapeutics Inc (NASDAQ: AKRO) kicked off on Monday, down -5.04% from the previous trading day, before settling in for the closing price of $56.19. Over the past 52 weeks, AKRO has traded in a range of $21.02-$58.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -5.28% over the last five years. While this was happening, its average annual earnings per share was recorded -1.23%. With a float of $71.76 million, this company’s outstanding shares have now reached $79.67 million.
The firm has a total of 63 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Akero Therapeutics Inc (AKRO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Akero Therapeutics Inc is 9.99%, while institutional ownership is 101.98%. The most recent insider transaction that took place on Jun 18 ’25, was worth 363,041. In this transaction President and CEO of this company sold 6,620 shares at a rate of $54.84, taking the stock ownership to the 549,867 shares. Before that another transaction happened on Jun 18 ’25, when Company’s Chief Technology Officer sold 848 for $54.84, making the entire transaction worth $46,504. This insider now owns 23,452 shares in total.
Akero Therapeutics Inc (AKRO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -1.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.29% during the next five years compared to -5.28% drop over the previous five years of trading.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Take a look at Akero Therapeutics Inc’s (AKRO) current performance indicators. Last quarter, stock had a quick ratio of 16.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -4.36 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Analysing the last 5-days average volume posted by the [Akero Therapeutics Inc, AKRO], we can find that recorded value of 2.64 million was better than the volume posted last year of 1.53 million. As of the previous 9 days, the stock’s Stochastic %D was 57.97%.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 82.99%, which indicates a significant increase from 32.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 33.55% in the past 14 days, which was lower than the 64.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.38, while its 200-day Moving Average is $38.42. Now, the first resistance to watch is $55.56. This is followed by the second major resistance level at $57.76. The third major resistance level sits at $59.01. If the price goes on to break the first support level at $52.11, it is likely to go to the next support level at $50.86. Now, if the price goes above the second support level, the third support stands at $48.66.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
The company with the Market Capitalisation of 4.25 billion has total of 79,718K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -252,060 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -70,730 K.
